Company intelligence

PureTech

As of September 5, 2026, PureTech had a market capitalization of $0.42B (companiesmarketcap.com).

PureTech Health is a publicly traded biopharmaceutical company that discovers, develops, and commercializes breakthrough medicines by founding and funding a network of subsidiary companies, including Celea Therapeutics.

BiotechPublic · PRTCBoston, Massachusetts, USAFounded 2005Founders: Daphne ZoharPublic companyWebsite ↗
Last verified Sep 5, 2026

PureTech at a glance

As of
Market cap
$0.42B[1]
September 2026
Founded
2005[2]
Headquarters
Boston, Massachusetts, USA[3]
  1. [1] Market cap: companiesmarketcap.com, September 5, 2026
  2. [2] Founded: Wikipedia (retrieved September 5, 2026)
  3. [3] Headquarters: Wikipedia (retrieved September 5, 2026)

PureTech profile

written 2026-11-20

PureTech Health is a hub-and-spoke biotech that spins drug programs into startups such as Karuna, Seaport and Celea. Celea raised $180 million in July 2026.

What PureTech is

PureTech Health is a biotechnology firm that creates and backs startup companies. BioPharma Dive describes it as a company with a web of startup subsidiaries. The outlet says PureTech works through a hub-and-spoke model. A central firm, the hub, spins drug programs into startup spokes.[1],[2]

BioPharma Dive's Jacob Bell writes that PureTech discovers, develops or acquires promising drug programs, then spins them out into individual startups that are kept at arm's reach. BioPharma Dive notes that the approach has not been fully embraced by Wall Street. It also credits the model with a notable success in Karuna Therapeutics, which developed the schizophrenia drug Cobenfy and sold to Bristol Myers Squibb for $14 billion.[1],[2]

Bell reports that the Bristol Myers deal has already generated around $1.1 billion in gross proceeds for PureTech. He writes that PureTech initially put in less than $19 million to get Karuna off the ground. He adds that the deal could result in upwards of $400 million more if certain regulatory and commercial milestones are hit.[2]

Seaport Therapeutics

Seaport Therapeutics is a neuropsychiatric drug company that PureTech launched on April 9, 2024. STAT's Andrew Joseph reported that it came from the team behind Karuna and that Daphne Zohar, the founding CEO of PureTech, would lead it. Seaport raised a $100 million Series A round, backed by the same investors who first funded Karuna: ARCH Venture Partners, Sofinnova Investments and Third Rock Ventures.[3],[2],[1],[4]

Chemical & Engineering News described the round as oversubscribed and led by ARCH Venture Partners and Sofinnova, with Third Rock Ventures and PureTech also participating. It said Zohar would serve as Seaport's CEO and that Steven Paul, former CEO of Karuna, would chair the board.[4]

BioPharma Dive explains that Seaport's Glyph platform attaches drugs to dietary fat molecules. This reroutes them to the lymphatic system so more of the drug keeps circulating through the body, with fewer side effects. The outlet says the most advanced candidate at launch was a prodrug of allopregnanolone, being developed for anxious depression.[2]

The launch came with a leadership change at PureTech. BioPharma Dive reports that Zohar stepped down from PureTech's board to lead Seaport. PureTech senior executive Bharatt Chowrira became CEO of PureTech, and Eric Elenko, a co-founder, was promoted to president.[2]

Celea Therapeutics

On Aug. 12, 2025, BioPharma Dive's Delilah Alvarado reported that PureTech had launched Celea Therapeutics. The company was formed to develop deupirfenidone, also known as LYT-100, a drug candidate initially being evaluated against idiopathic pulmonary fibrosis. Alvarado describes deupirfenidone as a chemically improved version of pirfenidone, a drug used to slow disease progression by reducing the formation of scar tissue in the lungs.[1]

She writes that Sven Dethlefs, who had led the deupirfenidone program inside PureTech for a year, would lead Celea. Before joining PureTech, Dethlefs was the CEO of Teva North America. BioPharma Dive says PureTech planned to seek outside funding to advance the program through testing and commercialization.[1]

Clinical Trials Arena reported on July 3, 2026 that Celea had secured $180m in financing to support a pivotal Phase III trial called SURPASS-IPF. Investors included RA Capital Management, PureTech Health, Leaps by Bayer, a major US healthcare fund and a sovereign wealth fund.[5]

The trial is a global, double-blind, head-to-head study. It compares deupirfenidone with pirfenidone in adults with idiopathic pulmonary fibrosis who are not on background therapy. The primary endpoint is the change from baseline in absolute forced vital capacity, a measure of lung function. Clinical Trials Arena adds that deupirfenidone has received orphan drug designation from both the European Commission and the US Food and Drug Administration.[5]

Is something wrong on this page?

Company Snapshot

PureTech is a biotech company, based in Boston, Massachusetts, USA, founded 2005 by Daphne Zohar.

Recent changes

  1. Sep 5, 2026First reported market cap: $0.42B companiesmarketcap.com

Latest Pulse

  1. Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis DrugCelea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.→
  2. Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3PureTech-founded Celea Therapeutics raised $180 million to fund a head-to-head Phase 3 trial testing its drug deupirfenidone against the current standard of care for idiopathic pulmonary fibrosis.→

Coverage Timeline

newest first
  1. Jul 2, 2026FUNDINGCelea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug$180M Series B→
  2. Jul 2, 2026FUNDINGCelea Therapeutics Raises $180M to Push Lung Drug Into Phase 3$180 million→

All Coverage

Value Add Research

Related Companies

PureTech FAQ

What is PureTech's market cap?

PureTech's market capitalization was $0.42B as of September 5, 2026, according to companiesmarketcap.com.

Is PureTech publicly traded?

Yes. PureTech trades under the ticker PRTC, with a market cap of $0.42B (September 5, 2026, companiesmarketcap.com).

When was PureTech founded and where is it based?

PureTech was founded in 2005 and is headquartered in Boston, Massachusetts, USA, according to Wikipedia.

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data ·